Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

Abstract Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BTZ; n = 138) or LEN (n = 183) MT from two...

Full description

Bibliographic Details
Main Authors: Marc-Andrea Baertsch, Elias K. Mai, Thomas Hielscher, Uta Bertsch, Hans J. Salwender, Markus Munder, Stephan Fuhrmann, Ulrich Dührsen, Peter Brossart, Kai Neben, Jana Schlenzka, Christina Kunz, Marc S. Raab, Jens Hillengaß, Anna Jauch, Anja Seckinger, Dirk Hose, Steffen Luntz, Pieter Sonneveld, Henk Lokhorst, Hans Martin, Martin Goerner, Martin Hoffmann, Hans-Walter Lindemann, Helga Bernhard, Igor W. Blau, Christof Scheid, Britta Besemer, Katja C. Weisel, Mathias Hänel, Jan Dürig, Hartmut Goldschmidt, German-Speaking Myeloma Multicenter Group (GMMG)
Format: Article
Language:English
Published: Nature Publishing Group 2021-01-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-020-00390-3

Internet

https://doi.org/10.1038/s41408-020-00390-3

Similar Items